Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 734

1.

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J.

J Clin Oncol. 2009 Aug 10;27(23):3836-41. doi: 10.1200/JCO.2008.20.8355.

PMID:
19597027
2.

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP.

J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034.

PMID:
19652060
3.

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O.

Clin Cancer Res. 2011 Dec 1;17(23):7462-9. doi: 10.1158/1078-0432.CCR-11-0534.

4.

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.

J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541.

PMID:
19652055
5.

Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.

Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S.

J Clin Oncol. 2009 Sep 20;27(27):4481-6. doi: 10.1200/JCO.2008.21.1862.

PMID:
19687333
6.

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G.

J Clin Oncol. 2008 Mar 1;26(7):1135-41. doi: 10.1200/JCO.2007.14.3685.

PMID:
18309949
7.

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.

Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group..

Eur J Cancer. 2011 Nov;47(17):2592-602. doi: 10.1016/j.ejca.2011.07.014.

PMID:
21889330
8.

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.

Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD.

Lung Cancer. 2008 Jun;60(3):374-80.

PMID:
18054408
9.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI.

Lancet Oncol. 2007 Nov;8(11):975-84.

PMID:
17959415
10.

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.

McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ.

Cancer. 2015 May 15;121(10):1620-7. doi: 10.1002/cncr.29227.

11.

Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study.

Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O'Brien M, Kosmidis P, Huat TE, Pinel MC, Colin C, Douillard JY.

Br J Cancer. 2006 May 22;94(10):1383-8.

12.

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.

Lung Cancer. 2009 Jun;64(3):319-25. doi: 10.1016/j.lungcan.2008.10.014.

PMID:
19095327
13.

Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.

Wibmer T, Kropf C, Merk T, Schumann C, Hombach V, Krüger S.

Lung Cancer. 2008 May;60(2):231-9.

PMID:
18006111
14.

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.

PMID:
16053664
15.

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.

Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.

Lung Cancer. 2009 Apr;64(1):60-5. doi: 10.1016/j.lungcan.2008.06.017.

PMID:
18692272
16.

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J.

Lung Cancer. 2008 Jul;61(1):82-90. doi: 10.1016/j.lungcan.2007.12.011.

PMID:
18255187
17.

Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.

Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R.

J Clin Oncol. 2011 Nov 1;29(31):4129-36. doi: 10.1200/JCO.2010.34.4127.

PMID:
21969509
18.

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.

Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H; S-1 Cooperative Study Group (Lung Cancer Working Group)..

Br J Cancer. 2001 Sep 28;85(7):939-43.

19.

A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer.

Rossi D, Catalano V, Alessandroni P, Fedeli A, Fedeli SL, Giordani P, Baldelli AM, Casadei V, Ceccolini M, Ugolini M, Dennetta D, Catalano G.

Clin Lung Cancer. 2007 May;8(6):382-5.

PMID:
17562239
20.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ.

J Clin Oncol. 2007 Aug 10;25(23):3448-55. Erratum in: J Clin Oncol. 2007 Nov 20;25(33):5339. Edelman, Mark [corrected to Edelman, Martin J].

PMID:
17606973

Supplemental Content

Support Center